Times being what they are, most of us are on more medications than we'd like to think about. And there is big money in big pharma, to the tune of billions. With so much money in play, big greed is sure to be sniffing around.
Drugs have side-effects (have you watched a pharmaceutical commercial lately? One might almost be safer with the disease.), and, if serious enough, these can cause injury, death, recalls, and big losses. L. J. Sellers takes this situation to spin a tale of a wonder-drug, its devastating effect, and just how far one might go in the name of greed in her new book, THE SUICIDE EFFECT.
Sula Moreno works as a public relations officer for Prolabs, a pharmaceutical developer in Eugene, Oregon. Prolabs has developed a new antidepressant sure to capture the lion's share of the market, and, primarily on the strength of this upcoming drug release, is in merger talks with a larger company. Prolabs' CEO, Karl Rudker, is banking heavily on the merger for a number of reasons, not the least of which is the precarious financial condition into which he has led the company. All will be well, though, with the merger and the release of the new drug, Nexapra.
The head researcher and discoverer of the drug threatens to cause a serious delay when she informs Rudker of a problem with Nexapra that presents a high risk of suicide in a subset of the population. Sula Moreno overhears the argument between the two, and becomes ensnared in resulting danger, as she tries to uncover the truth about Nexapra against a very determined CEO.
This is a thriller that will make you think twice about the next prescription you take.